本研究通过前瞻性试验的事后分析，首次证实基于诊断活检组织的Decipher基因组分类器（GC）评分（≥0.45）可独立预测前列腺癌（PCa）局灶治疗失败风险（6个月失败率46% v 21%，OR 2.61；18个月76% v 44%，OR 3.58），为个体化治疗选择提供了关键分子标志物。 能够预测 ...

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

You could do worse than to confuse the meanings of "code" and "cipher"—even cryptographers sometime use the terms as though they had the same meaning. There is, however, a definite distinction between ...

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...

The Algorand Foundation revealed the agenda for its second annual Decipher conference today, featuring leading thinkers, builders and founders from across the blockchain landscape. Decipher is to be ...

Imagine having increased muscle weakness for two years before figuring out the cause. That is the shared experience of myasthenia gravis patients. Canadian startup Decipher MedTech is developing a ...